Transcriptional reprogramming by mutated IRF4 in lymphoma.
Saved in:
| Title: | Transcriptional reprogramming by mutated IRF4 in lymphoma. |
|---|---|
| Authors: | Schleussner N; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Cauchy P; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; University Medical Center Freiburg, 79106, Freiburg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Franke V; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Giefing M; Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland.; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany., Fornes O; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Vankadari N; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3000, Australia., Assi SA; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Costanza M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Weniger MA; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Akalin A; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Anagnostopoulos I; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Bukur T; TRON gGmbH - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany., Casarotto MG; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Damm F; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Daumke O; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Edginton-White B; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Gebhardt JCM; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Grau M; Department of Physics, University of Marburg, 35052, Marburg, Germany.; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Grunwald S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Hansmann ML; Frankfurt Institute of Advanced Studies, Frankfurt am Main, Germany.; Institute for Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany., Hartmann S; Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany., Huber L; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Kärgel E; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Lusatis S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Noerenberg D; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Obier N; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Pannicke U; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany., Fischer A; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Reisser A; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Rosenwald A; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Schwarz K; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Ulm, Germany., Sundararaj S; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Weilemann A; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Winkler W; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Xu W; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Lenz G; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Rajewsky K; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Immune Regulation and Cancer, 13125, Berlin, Germany., Wasserman WW; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Cockerill PN; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Scheidereit C; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Siebert R; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany.; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Küppers R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Grosschedl R; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Janz M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Bonifer C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Mathas S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany. stephan.mathas@charite.de.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany. stephan.mathas@charite.de.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany. stephan.mathas@charite.de.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. stephan.mathas@charite.de. |
| Source: | Nature communications [Nat Commun] 2023 Nov 07; Vol. 14 (1), pp. 6947. Date of Electronic Publication: 2023 Nov 07. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
